Dernières nouvelles pour Manchester United (NYSE:MANU) Stock

Manchester United

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, and sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which the majority of the revenue is generated including Commercial, Broadcasting, and Matchday.

Manchester United Ltd. Class A Ordinary Shares

Manchester United PLC

MANUKA RES LTD by MANUKA RES LTD.

MANUFACTURED HOUSING PROP by Manufactured Housing Properties Inc.

Manufactured Housing Properties Inc

Manuka Inc

Manulife Financial Corporation Common Stock

Manulife Financial Corp

MANULIFE PFD CL 1 SER 19 by Manulife Financial Corp.

MANULIFE FINCL PFD A 2 by Manulife Financial Corp.

MANULIFE FINCL PFD A 3 by Manulife Financial Corp.

Manulife US REIT Units Real Estate Investment Trust Reg S

Manulife US REIT

Hedge Funds

General

UBER

13F Shows Tiger Global Exited 2.59 Million Share Stake In Uber Technologies Inc

RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up
RP-A601 promoted increased protein expression and desmosomal localization of Plakophilin-2 (PKP2), Desmocollin-2, and Cadherin-2 in all three patients
Improvement or stabilization observed in arrhythmia burden, heart function, and quality of life in all patients
No further dose escalation planned
Investor webinar to be held later today at 4:30 p.m. ET
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frocketpharma.com%2F&amp;esheet=54255677&amp;newsitemid=20250515788680&amp;lan=en-US&amp;anchor=Rocket+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=f90cf1c20b0ffee2a3295bbff43afe81">Rocket Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced preliminary data from the Phase 1 clinical trial of RP-A601 for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 showed a well-tolerated safety profile with no dose-limiting toxicities, increased PKP2 protein expression, and preliminary indications of improvement or stabilization in arrhythmia burden, heart function, and quality of life in all three patients followed for up to 12 months. Results were presented today as a late-breaking oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) and will be discussed on a company webinar today at 4:30 p.m. ET.

Biotech

News

RCKT

Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial Of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy

RDDT

13F Shows Tiger Global Increased Stake In Reddit Inc By 1.22 Million Shares

Hovnanian Enterprises Announces Strategic Partnership Between K. Hovnanian M.E. Investments And Saudi Arabia's NHC To Advance Vision 2030

NVDA

13F Shows Tiger Global Increased Stake In Nvidia Corp By 1.28 Million Shares

WIIM

Boston Omaha shares are trading lower. The company reported Q1 financial results.

A ban on buying and selling stocks and options by <a href="https://www.benzinga.com/topic/congress-trading">members of Congress </a>continues to heat up with a new bill proposed and several notable figures, including President Donald Trump, supporting the effort.
Speaker of the House Mike Johnson (R-La.) is also in favor of a ban according to recent comments.
What Happened: Sen. Josh Hawley (R-Mo.) <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">has introduced the</a> Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).
Pelosi, whose husband is a frequent stock trader and venture capitalist, likely doesn't support the bill that would limit her husband&#8217;s transactions while she's in office.
One person showing support for the bill is Johnson, who, according to<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noopener"> Benzinga's Government Trades page, </a>has not bought and sold any stocks.
"I'm in favor of that," Johnson <a href="https://x.com/Breaking911/status/1922714214965141574">told </a>reporters recently. "I don't think we should have any appearance of impropriety."
Johnson acknowledged that the counterargument to the ban is that Congress members&#8217; salaries haven't kept up with inflation, and if this trend continues, there could be fewer qualified people running for Congress.
The Speaker said that stock trading activity by members of Congress has been ruined by "a few bad actors."
"I think it's been abused in the past."
Johnson said there is zero tolerance for "anything resembling insider trading."
President Trump also recently <a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said </a>he would support such a ban, and that he would sign the bill if it was passed by Congress
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought</a>
Why It's Important: Hawley said the bill will help "restore Americans' trust in our nation's legislative body."
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
With ongoing debates about<a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin" target="_blank" rel="noreferrer noopener">&nbsp;potential conflicts of interest&nbsp;</a>in congressional trading, Representative&nbsp;Ro Khanna&nbsp;(D-Calif.) previously told Benzinga he would continue advocating for a congressional vote to ban the practice.
"We should have a vote on it," Khanna told Benzinga.
Khanna said that despite his continued speeches in the House advocating for a ban on stock trading, there is a &#8220;collective shrug&#8221; in Congress regarding the issue.
Members of Congress are currently allowed to buy and sell stocks and options as long as they properly disclose the transactions within 45 days.
Multiple transactions have been flagged by Benzinga and other outlets that point to potential conflicts of interest over the timing of the trades.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener"> </a><a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noopener">both Republican</a> and Democratic members of Congress are profiting from buying and selling stocks and options while in office. Some trades have questionable timing or are connected to committees they serve on.
An analysis of recent trading activity highlights the members of Congress with the highest number of transactions and largest dollar volumes—those most active in stock trading.
<ul class="wp-block-list">
<li>Thomas Kean Jr., Representative (R-N.J.)</li>
<li>Josh Gottheimer, Representative (D-N.J.)</li>
<li>Julie Johnson, Representative (D-Texas)</li>
<li>Markwayne Mullin, Senator (R-Okla.)</li>
<li>Tommy Tuberville, Senator (R-Ala.)</li>
<li>Marjorie Taylor Greene, Representative (R-Ga.)</li>
<li>Nancy Pelosi, Representative (D-Calif.)</li>
</ul>
There are also the best traders by return in 2024 as tracked by UnusualWhales.
Here&#8217;s a look at the <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">top 10 for 2024:</a>
<ol start="1" class="wp-block-list">
<li>David Rouzer&nbsp;(R-N.C.), Representative, +149.0%</li>
<li>Debbie Schultz&nbsp;(D-Fla.), Representative, +142.3%</li>
<li>Ron Wyden&nbsp;(D-Ore.), Senator, +123.8%</li>
<li>Roger Williams&nbsp;(R-Texas), Representative, +111.2%</li>
<li>Morgan McGarvey&nbsp;(D-Ky.), Representative, +105.8%</li>
<li>Larry Bucshon&nbsp;(R-Ind.), Representative, +98.6%</li>
<li>Pete Sessions&nbsp;(R-Texas), Representative, +77.5%</li>
<li>Susan Collins&nbsp;(R-Maine), Senator, +77.5%</li>
<li>David Kustoff&nbsp;(R-Tenn.), Representative, +71.5%</li>
<li>Nancy Pelosi&nbsp;(D-Calif.), Representative, +70.9%</li>
</ol>
Several of these figures have appeared on past lists. Rouzer was ranked fourth in the 2023 report and seventh in the 2021 report. Schultz ranked second in the 2022 report. Wyden ranked sixth in the 2023 report. Sessions ranked 10th&nbsp;in the 2023 report. Pelosi was ranked ninth in the 2023 report and ranked sixth in the 2021 report.
A ban on congressional stock trading would fulfill a long-standing call from retail investors and tracking sites alike. It could also mean the end of ETFs that track Congressional trading activity, such as the Unusual Whales Subversive Democratic Trading ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NANC#BATS">NANC</a>) and the Unusual Whales Subversive Republican Trading ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/GOP#BATS">GOP</a>).
Hawley&#8217;s bill does not mention cryptocurrency like&nbsp;Bitcoin&nbsp;(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), with several members of Congress buying Bitcoin&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45018551/senator-on-digital-assets-committee-buys-more-bitcoin-etf-shares-2025-is-the-year-for-digital-assets" target="_blank" rel="noreferrer noopener">and Bitcoin ETFs</a>&nbsp;over the last year as the U.S. looks to establish a Bitcoin Strategic Reserve.
The PELOSI Act is unlikely to pass Congress this year. On the prediction market Polymarket, there is only a 14% <a href="https://polymarket.com/event/us-congress-stock-trading-ban-in-2025?tid=1745937690521&amp;utm_source=twitter&amp;utm_medium=post&amp;utm_campaign=%40polymarket&amp;dub_id=XdIywVN23HqZXXSU" target="_blank" rel="noopener">chance </a>that Congress stock trading will be banned in 2025. On <a href="https://kalshi.com/markets/kxtrdban/congress-banned-from-trading-stocks">Kalshi</a>, the odds are currently listed at 11%.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent051525">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent051525"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15141857/Picture1-3-1024x330.png" alt="" class="wp-image-917021" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15141857/Picture1-3-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15141857/Picture1-3-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15141857/Picture1-3-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15141857/Picture1-3.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Politics

$BTC

NANC

Speaker Johnson Backs Congressional Stock Trading Ban: Ruined By 'A Few Bad Actors'

Eric Trump, executive vice president of the Trump Organization on Thursday described Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) accumulation as a &#8220;race to the top,&#8221; highlighting a surge in interest from major institutions and wealthy individuals, signaling a shift in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">attitudes toward digital assets</a>.
What Happened: &#8220;It really is kind of a race to the top right now,&#8221; Trump said during his <a href="https://x.com/WatcherGuru/status/1923070649309761804">remarks</a> at Consensus. &#8220;There's a lot of people who are running very hard at this mission.&#8221;
Drawing on a recent anecdote, Trump said even senior executives at traditional financial institutions, once openly skeptical, are now actively seeking to enter the Bitcoin market. &#8220;A year ago, he was saying, &#8216;Bitcoin's funny money.&#8217; The other day he goes, ‘Eric, where do I buy&#8230; how do I get into this world?'"
Trump said this sentiment shift is consistent across sectors, from Wall Street to global investment offices. &#8220;I hear it from sovereign wealth funds, hear it from the wealthiest families, I hear it from the biggest companies,&#8221; he said.
Why It Matters: The comments come as Bitcoin continues to trade near record highs, supported by rising institutional interest, ETF inflows, and growing recognition of the asset's monetary properties in macroeconomic circles.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45444794/bitcoin-is-starting-to-outperform-gold-jpmorgan">Bitcoin Is Starting To Outperform Gold: JPMorgan</a>
Trump emphasized that legacy resistance is fading, noting that &#8220;people who were staunchly against it&#8230; are coming around in a massive way.&#8221;
While he didn't outline specific investment plans, the tone of his remarks strongly aligned with the broader narrative of capital rotation into crypto from traditional finance. 
"I promise you we're going to beat them in that marathon,&#8221; he said.
Eric Trump serves as a Web3 Ambassador for World Liberty Financial, a Trump-family-led decentralized finance platform. 
He actively promotes its stablecoin and DeFi initiatives, leveraging significant investments and partnerships.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Eric Trump: Bitcoin Accumulation Is 'A Race To The Top'

<a href="https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml" title="https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml">https://www.sec.gov/Archives/edgar/data/1998597/000090266425002348/xslForm13F_X02/infotable.xml</a>

FRPT

TRMB

WOLF

JANA Partners 13F Filing Shows Increased Stake In Lamb Weston By 854,087 Shares; Increased Stake In Markel Group By 47,096 Shares; Increased Stake In Rapid7 By 415,927 Shares; Decreased Stake In Trimble By 232,861 Shares; Sold Complete Stake In Wolfspeed; New Position Of Freshpet With 734,763 Shares

<a href="https://www.globenewswire.com/Tracker?data=V4p4HYBM4nfxb1-5UUB4gwuVm1ELD_1w6CHJ2OD-rFyA3NnWD0ESScEwDhI8H3pYC1W5FHu4ztfw4W2hqu3X9BDI3ETCBMgB-EPmUnLbHU0=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the "Notes") under its European Medium Term Note (EMTN) program.
The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in <a href="https://www.globenewswire.com/Tracker?data=27zD7zL8K-bIGWXu-UdjhCRFTCuh5XEkUKbt1JfV5_BJfjnxuUfdsHRzIsPVF_dIj7GaisBoYSapOB_Rl3sLEXQ5oLTSsVSnwirMvx_Kd18LKZ9zrkPEK35i7dn8NFPkDMXy0M_cAQshhp3FPsAhNXQ6SOHXBsqXwowEeqoN4-ZEso6f-YiSYS-GWJCC4yD_0taQaZIf7ujVV_yXoWVKlg==">Philips' Sustainable Finance Framework</a>.
The issue price for the Notes due 2030 is 99.859% with a Coupon of 3.250%, resulting in a yield of 3.281% and the issue price for the Notes due 2035 is 99.595% with a Coupon of 4.000%, resulting in a yield of 4.050%. The 5 and 10 year tranches were oversubscribed by more than 3 and 4 times, respectively.

Royal Philips Prices Offering Of EUR 500M Fixed Rate Notes Due 2030 And EUR 500M Fixed Rate Notes Due 2035 Under EMTN Program

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares are volatile Thursday but have climbed more than 50% over the past month as investors react to <a href="https://www.benzinga.com/25/05/45379735/quantum-computing-stocks-are-facing-selling-pressure-tuesday-whats-going-on">first-quarter results</a> and technical updates.
What To Know: The company reported $15 million in revenue for first-quarter, a sharp increase from the $2.4 million it posted a year earlier. The growth was mainly due to its first recognized sale of the Advantage quantum computing system and increased use of its hybrid solutions.
D-Wave reported a net loss of 2 cents per share, better than analyst expectations for a 7-cent loss. Gross profit improved significantly, reaching $13.9 million with a gross margin of over 92%. The company also reported a cash balance of $304.3 million, helped by proceeds from its third equity offering.
In addition to financials, D-Wave disclosed that it demonstrated quantum performance on a real-world simulation problem that it says was faster than a classical supercomputer could manage. It also highlighted collaborations with Ford Otosan for vehicle scheduling and with Japan Tobacco's pharma division for drug research. D-Wave said its Advantage2 system, designed for defense use, is undergoing final testing.
The company also discussed research into blockchain hashing using quantum computing, which it claims could reduce energy use significantly. This led to interest from organizations in the blockchain space.
QBTS Price Action: D-wave Quantum shares were down 0.72% at $11 at the time of writing, according to Benzinga Pro.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45447252/wall-street-wavers-as-unh-tumbles-foot-locker-soars-whats-driving-markets-thursday">Wall Street Wavers As UNH Tumbles, Foot Locker Soars: What&#8217;s Driving Markets Thursday? </a></li>
</ul>
Image Via Shutterstock.

Movers

QBTS

What's Going On With D-Wave Quantum Shares This Month?

Looking into the current session, Aehr Test System Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares are trading at $9.42, after a 0.32% spike. Moreover, over the past month, the stock spiked by 14.46%, but in the past year, decreased by 18.56%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747335683_0.png" alt="Past Year Chart" />

<h3>Aehr Test System P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 65.54 in the Semiconductors &amp; Semiconductor Equipment industry, Aehr Test System Inc. has a lower P/E ratio of 12.04. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747335683_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

AEHR

A Look Into Aehr Test System Inc's Price Over Earnings

Across the recent three months, 7 analysts have shared their insights on Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBDC#NYSE">OBDC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.5, a high estimate of $17.00, and a low estimate of $14.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.15%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335680_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Blue Owl Capital is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Hurwit</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$14.50</td>
<td>$15.10</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blue Owl Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Blue Owl Capital compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Blue Owl Capital's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blue Owl Capital's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OBDC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blue Owl Capital analyst ratings.</a>
<h2>All You Need to Know About Blue Owl Capital</h2>
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
<h3>Blue Owl Capital: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Blue Owl Capital showcased positive performance, achieving a revenue growth rate of 29.09% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Blue Owl Capital's net margin is impressive, surpassing industry averages. With a net margin of 92.26%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Blue Owl Capital's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Blue Owl Capital's ROA stands out, surpassing industry averages. With an impressive ROA of 1.51%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.31.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OBDC

Expert Outlook: Blue Owl Capital Through The Eyes Of 7 Analysts

Deep-pocketed investors have adopted a bullish approach towards Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TSLA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 992 extraordinary options activities for Tesla. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 41% bearish. Among these notable options, 464 are puts, totaling $48,476,907, and 528 are calls, amounting to $44,045,025.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $960.0 for Tesla over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tesla's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tesla's whale activity within a strike price range from $5.0 to $960.0 in the last 30 days. 
<h3>Tesla Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747335674_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$10.75</td>
<td>$10.7</td>
<td>$10.75</td>
<td>$370.00</td>
<td>$1.6M</td>
<td>8.2K</td>
<td>11.3K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.35</td>
<td>$9.25</td>
<td>$9.3</td>
<td>$400.00</td>
<td>$508.7K</td>
<td>34.9K</td>
<td>17.1K</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$433.35</td>
<td>$432.6</td>
<td>$432.6</td>
<td>$770.00</td>
<td>$432.6K</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$5.3</td>
<td>$5.25</td>
<td>$5.3</td>
<td>$400.00</td>
<td>$271.4K</td>
<td>13.1K</td>
<td>16.6K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$44.55</td>
<td>$44.3</td>
<td>$44.55</td>
<td>$400.00</td>
<td>$209.1K</td>
<td>4.1K</td>
<td>729</td>
</tr>
</tbody>
</table>

<h3>About Tesla</h3>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and offer a robotaxi service. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
After a thorough review of the options trading surrounding Tesla, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Tesla</h3>
<ul>
<li>Trading volume stands at 79,342,450, with TSLA's price down by -1.35%, positioned at $342.98.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>Professional Analyst Ratings for Tesla</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $356.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Tesla, targeting a price of $450. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $350. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Tesla with a target price of $307. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Tesla, which currently sits at a price target of $355. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Tesla, targeting a price of $320. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tesla options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

TSLA

Market Whales and Their Recent Bets on TSLA Options

Analysts' ratings for DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.75, a high estimate of $18.00, and a low estimate of $9.00. Observing a 7.84% increase, the current average has risen from the previous average price target of $12.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335670_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of DLocal's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jorge Kuri</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Guilherme Grespan</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DLocal. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of DLocal compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DLocal's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DLocal's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DLO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DLocal analyst ratings.</a>
<h2>Unveiling the Story Behind DLocal</h2>
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
<h3>DLocal: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining DLocal's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.77% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: DLocal's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.52% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): DLocal's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.28%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): DLocal's ROA stands out, surpassing industry averages. With an impressive ROA of 2.53%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing DLocal: Insights From 4 Financial Analysts

Financial giants have made a conspicuous bearish move on Cloudflare. Our analysis of options history for Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) revealed 21 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $72,031, and 19 were calls, valued at $1,254,265.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $115.0 to $165.0 for Cloudflare during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cloudflare's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cloudflare's whale activity within a strike price range from $115.0 to $165.0 in the last 30 days. 
<h3>Cloudflare Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747335668_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.3</td>
<td>$39.55</td>
<td>$39.61</td>
<td>$115.00</td>
<td>$131.3K</td>
<td>885</td>
<td align="right">385</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$39.0</td>
<td>$38.7</td>
<td>$38.76</td>
<td>$115.00</td>
<td>$128.5K</td>
<td>3.4K</td>
<td align="right">643</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.3</td>
<td>$39.55</td>
<td>$39.73</td>
<td>$115.00</td>
<td>$126.9K</td>
<td>885</td>
<td align="right">385</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.3</td>
<td>$39.55</td>
<td>$39.55</td>
<td>$115.00</td>
<td>$126.8K</td>
<td>885</td>
<td align="right">385</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$39.0</td>
<td>$38.7</td>
<td>$38.88</td>
<td>$115.00</td>
<td>$124.2K</td>
<td>3.4K</td>
<td align="right">643</td>
</tr>
</tbody>
</table>

<h3>About Cloudflare</h3>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
<h3>Where Is Cloudflare Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,697,870, with NET's price down by -1.0%, positioned at $152.95.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 77 days.</li>
</ul>
<h3>What The Experts Say On Cloudflare</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $153.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna has decided to maintain their Neutral rating on Cloudflare, which currently sits at a price target of $140. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Cloudflare, targeting a price of $165. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Cloudflare, targeting a price of $150. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $151. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Cloudflare with a target price of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cloudflare with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Cloudflare Unusual Options Activity For May 15

Financial giants have made a conspicuous bearish move on KLA. Our analysis of options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) revealed 13 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $1,152,840, and 8 were calls, valued at $817,079.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $580.0 to $1040.0 for KLA over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in KLA's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to KLA's substantial trades, within a strike price spectrum from $580.0 to $1040.0 over the preceding 30 days.
<h3>KLA 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747335663_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$66.3</td>
<td>$61.4</td>
<td>$64.1</td>
<td>$740.00</td>
<td>$961.5K</td>
<td align="right">100</td>
<td align="right">150</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$221.7</td>
<td>$218.0</td>
<td>$221.7</td>
<td>$580.00</td>
<td>$221.7K</td>
<td align="right">44</td>
<td align="right">10</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$225.0</td>
<td>$220.0</td>
<td>$220.0</td>
<td>$620.00</td>
<td>$220.0K</td>
<td align="right">34</td>
<td align="right">10</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$166.1</td>
<td>$161.0</td>
<td>$161.0</td>
<td>$820.00</td>
<td>$177.1K</td>
<td align="right">24</td>
<td align="right">0</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$28.1</td>
<td>$26.7</td>
<td>$28.1</td>
<td>$710.00</td>
<td>$84.3K</td>
<td align="right">4</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About KLA</h3>
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
Following our analysis of the options activities associated with KLA, we pivot to a closer look at the company's own performance.
<h3>KLA's Current Market Status</h3>
<ul>
<li>Trading volume stands at 578,618, with KLAC's price down by -0.96%, positioned at $797.27.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>Professional Analyst Ratings for KLA</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $779.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Neutral rating for KLA, targeting a price of $800. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on KLA, which currently sits at a price target of $740. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on KLA, maintaining a target price of $868. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on KLA with a target price of $590. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on KLA, maintaining a target price of $900. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for KLA with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

KLAC

Unpacking the Latest Options Trading Trends in KLA

In the preceding three months, 14 analysts have released ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Merit Medical Systems, presenting an average target of $111.93, a high estimate of $127.00, and a low estimate of $100.00. A 3.58% drop is evident in the current average compared to the previous average price target of $116.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$127.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$116.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Merit Medical Systems's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merit Medical Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Unveiling the Story Behind Merit Medical Systems</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>A Deep Dive into Merit Medical Systems's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.84%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Merit Medical Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MMSI

The Analyst Verdict: Merit Medical Systems In The Eyes Of 14 Experts

During the last three months, 4 analysts shared their evaluations of Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $118.25, a high estimate of $125.00, and a low estimate of $100.00. This current average reflects an increase of 3.5% from the previous average price target of $114.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335650_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Popular's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Schiraldi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Popular. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Popular compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Popular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Popular's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPOP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Popular analyst ratings.</a>
<h2>Get to Know Popular Better</h2>
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
<h3>Key Indicators: Popular's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Popular's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.81%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Popular's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 24.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.12%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Popular's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Popular's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

Analyst Expectations For Popular's Future

Across the recent three months, 7 analysts have shared their insights on JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.21, a high estimate of $5.00, and a low estimate of $3.00. A decline of 25.62% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335635_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of JetBlue Airways by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$4.25</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.25</td>
<td>$7.15</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.25</td>
<td>$5.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to JetBlue Airways. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of JetBlue Airways compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of JetBlue Airways's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of JetBlue Airways's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JBLU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on JetBlue Airways analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About JetBlue Airways</h2>
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic &amp; Canada segment.
<h3>JetBlue Airways: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, JetBlue Airways faced challenges, resulting in a decline of approximately -3.12% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: JetBlue Airways's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -9.72%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): JetBlue Airways's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -8.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): JetBlue Airways's ROA stands out, surpassing industry averages. With an impressive ROA of -1.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: JetBlue Airways's debt-to-equity ratio stands notably higher than the industry average, reaching 3.85. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JBLU

What 7 Analyst Ratings Have To Say About JetBlue Airways

Press Releases

Tiger® Beer Becomes the Official Beer Partner of Manchester United

Manchester United plc Announces the Appointment of Rúben Amorim as Head Coach

Manchester United plc Announces First Quarter Fiscal 2025 Earnings Report Date

Manchester United PLC Reports First Quarter Fiscal 2025 Results

Small Cap

Opinion

Strategic Investments Spark Renewed Interest in Multi-Club Ownership Models

Manchester United plc Announces Second Quarter Fiscal 2025 Earnings Report Date

Manchester United Plc Reports Second Quarter Fiscal 2025 Results

Manchester United plc Announces Transformation Plan to Strengthen Financial Sustainability and Modernise its Operating Structure

Tour 2025 Presented by Snapdragon: Manchester United to Join Premier League Summer Series

Manchester United Backs Government's Ambitious Growth Agenda With New Stadium Announcement

BREA

MANU

MSGS

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Media

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Vivid Seats

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Manchester United

Actualités

Dernières nouvelles pour Manchester United (NYSE:MANU) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL